AIM — AIM ImmunoTech Share News
0.000.00%
Last trade - 00:00- $8.65m
- $6.99m
- $0.09m
Brief: AIM Immunotech Inc Files For Mixed Shelf Offering Of Up To $100 Million - SEC Filing
Brief: AIM Immunotech Reports Fourth Quarter And Full Year 2024 Financial Results And Provides Corporate Update
Brief: Aim Immunotech Announces Notification Of Noncompliance With Additional NYSE American Continued Listing Standards
Brief: Kellner Group Urges Stockholders Of AIM Immunotech To Vote "For" All Four Kellner Group Nominees
Brief: Aim Immunotech Inc Says Glass Lewis Recommends Co's Shareholders Vote "For" Company Nominees Nancy K. Bryan, Thomas K. Equels And Dr. William M. Mitchell
Brief: ISS Recommends AIM ImmunoTech Shareholders Vote “FOR” Company Nominees Nancy K. Bryan and Dr. William M. Mitchell
Brief: AIM ImmunoTech Issues Presentation Detailing Why Shareholders Should NOT Elect Activist Group’s Nominees to the Board
Brief: Aim Immunotech Announces Cash Conservation Plan
Brief: Aim Immunotech Inc Files Definitive Proxy Statement And Sends Letter To Shareholders
Brief: Aim Immunotech Announces Pricing Of $1.26 Million Registered Direct Offering
Brief: Aim ImmunoTech- Compensation Committee Of Board Reviewed Compensation Arrangements Of CEO Thomas K. Equels
Brief: Todd Deutsch Ted Kellner Supplemented Previously Submitted Notice Of Intent Of Nominations To Aim Immunotech Board - SEC Filing
Brief: AIM Immunotech Analysis Of AMP-518 Complete Clinical Patient Data Underscores Ampligen's Potential To Improve Post-Covid Condition Of Fatigue
U.S. RESEARCH ROUNDUP-Adapthealth, Carnival, Phunware
Brief: Todd Deutsch Says Significant Change In AIM ImmunoTech's Board Is Urgently Needed - SEC Filing
U.S. RESEARCH ROUNDUP-Deckers Brands, NVIDIA, Workday
Brief: AIM Immunotech Announces First Dose Level In Phase 1B/2 Study Of Ampligen And Imfinzi As A Combination Therapy
Brief: AIM ImmunoTech Announces Interim Report Data From Study of Ampligen Combined with Pembrolizumab For Treatment Of Recurrent Ovarian Cancer
Brief: AIM Immunotech Outlines Recent Progress Across Clinical Development Pipeline And Provides Business Update